I
nflammatory bowel diseases (IBDs) are idiopathic disorders of the gastrointestinal tract, which are characterized by chronic relapsing intestinal inflammation. IBDs, such as Crohn's disease and ulcerative colitis, are associated with the upregulation of many acute-phase proteins (i.e., C-reactive protein, serum amyloid A [SAA] , and sIL-1Ra). The exploration of the biologic activities of acute-phase proteins has resulted in the development of biological therapeutics to treat IBD. 1 However, currently, there are no universally acceptable route by which these therapeutics can be administered efficiently. Moreover, the therapeutic potential of one of the most dynamically upregulated acute-phase proteins, lipocalin-2 (Lcn2; aka neutrophil gelatinase-associated lipocalin or NGAL, siderocalin, 24p3) is considerably unknown. 2, 3 Lcn2 is a small 25 kDa protein that is secreted by a variety of immune and nonimmune cells, particularly in response to inflammation. 2 The levels of circulating and mucosal Lcn2 are reported to increase by log orders of magnitude in various inflammatory conditions including IBD. [3] [4] [5] [6] [7] [8] [9] Previously, we have shown that fecal Lcn2 is a dynamic, sensitive, and noninvasive biomarker of gut inflammation. 3 Among its diverse physiological functions, one well-established role of Lcn2 is to sequester bacterial siderophores, such as enterobactin (Ent) and thus limit the growth of iron-dependent bacteria. 4, [10] [11] [12] In addition, Lcn2 also plays a role in facilitating the hypoferremia of inflammation and suppressing the generation of catalytic iron. 12 Such mechanisms suggest that the upregulation of Lcn2 during intestinal or systemic inflammation may mediate alterations in the gut microbiota, particularly during IBD. [13] [14] [15] Although Lcn2 deficiency has been shown to potentiate gut dysbiosis in mice and increase their susceptibility to colitis, 16, 17 the therapeutic potential of Lcn2 supplementation has yet to be elucidated.
Numerous therapeutic molecules have been developed to treat experimental colitis model; however, their utility is impeded by the high cost associated with long-term treatment. Such constraint could be potentially circumvented by using a recombinant lactic acid bacteria to deliver therapeutic biologicals. 18 The use of bacterial vector would allow for a more cost-effective and direct delivery of therapeutics to the site of inflammation and avoid the risk of systemic side effects. Lactococcus lactis genetically modified to secrete the antiinflammatory cytokine IL-10 is perhaps the most promising application of this strategy and had been demonstrated in several studies to be effective in treating gastrointestinal inflammation. 19, 20 Subsequent studies also elucidated the efficacy of various recombinant L. lactis in mitigating experimental colitis, including L. lactis bioengineered to provide mucosal delivery of IL-27, 21 transforming growth factor-b1, elafin, secretory leukocyte protease inhibitor, 22 and anti-tumor necrosis factor nanobodies. 23 Despite the feasibility of using L. lactis as a mucosal delivery vector, the efficacy of recombinant L. lactis is still critically affected by its inherent deficiencies to survive in the inflamed gut. Accordingly, we sought to provide evidence that the fitness of L. lactis could be further modified as an innovative strategy to improve its efficacy to treat experimental colitis.
In this study, we investigated the therapeutic potential of Lcn2 expression in augmenting the persistence and colonization of a probiotic bacterium in the inflamed gut. We demonstrated that ectopic expression of Lcn2 in L. lactis substantially augments its capacity to withstand a spectrum of environmental stressors, including adverse pH, bile acids, and H 2 O 2 -induced oxidative stress. We confirmed that L. lactis-secreted Lcn2 is bioactive in sequestering Ent (a bacterial siderophore, i.e., essential for Escherichia coli iron acquisition) and thus able to inhibit the growth of E. coli in vitro. Using the murine model of dextran sulfate sodium (DSS)-induced acute colitis, we provide evidence that Lcn2 expression confers a survival advantage to L. lactis and allows it to robustly colonize the inflamed gut than L. lactis harboring the empty vector. Furthermore, we demonstrate that Lcn2-expressing L. lactis is more effective than control L. lactis in mediating mucoprotection to colitic mice. Collectively, our results highlight that genetic modification of probiotic bacteria to produce and secrete Lcn2 may offer a feasible strategy to improve the stability, retention, and efficacy of probiotic bacteria in treating experimental colitis. Guaiacol (2-methoxyphenol) was obtained from Alfa Aesar (Ward Hill, MA). Erythromycin was purchased from Amresco (Solon, OH). The iron atomic absorption standard was purchased from RICCA Chemical Company. SYBR Green mix and qScript cDNA synthesis kit were procured from Quanta Biosciences (Beverly, MA). Mouse recombinant (rec)-Lcn2 (free from endotoxin, siderophore, and iron) was obtained from Cell Signaling. All other chemicals used in this study were reagent grade and procured from Sigma.
MATERIALS AND METHODS

Reagents
Mice
C57BL/6 wild-type (WT) mice were maintained and bred under specific pathogen-free conditions in the animal house facility at Pennsylvania State University, PA. Mice were housed in cages (max. 5 mice per cage) containing sawdust bedding and paper tissue nestlets and fed on chow-control diet ad libitum with unrestricted access to water throughout the study. The cages were kept at 238C and underwent a 12-hour light/dark phase cycle. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Pennsylvania State University.
Bacteria
L. lactis strain MG1363 was grown in M17 broth or agar (1.5% [wt/vol]) media supplemented with 0.5% glucose and incubated overnight under anaerobic conditions at 308C. Recombinant L. lactis strains were selected in M17 with 0.5% glucose in the presence of 5.0 mg/mL erythromycin (henceforth described as selective M17). K12 E. coli strain was acquired from the E. coli Genetic Stock Center, Yale University. Ent-overexpressing E. coli isogenic mutant ferrienterobactin permease (DfepA) was gifted from Dr. Kathleen Postle, Pennsylvania State University. Nonpathogenic WT K12 E. coli and DfepA were grown in LuriaBertani (LB) medium (Sigma) containing kanamycin (50 mg/mL) overnight at 378C. The bacterial colony-forming units (CFUs) were adjusted based on the optical density at 600 nm.
Construction of Recombinant Bacterial Strains
Murine Lcn2 cDNA (Sino Biological Inc. BDA, Beijing, China) was amplified using primers Lcn2-Spe1 5 0 -GGAC-TAGTCCTCAGTTGTCAAGCATTGGTCGG-3 0 and Lcn2-BamH1 5 0 -CGCGGATCCGCGACCATGGCCCTGAGTGTCA-3 0 . Amplicon and plasmid pT1NX (LMBP 3498; available from the BCCM/LMBP Plasmid Collection, Ghent University, Belgium; http://bccm.belspo.be/about-us/bccm-lmbp) were then digested by restriction enzymes BamH1 and Spe1 (Roche) to generate compatible ends. Lcn2 transgene was ligated (T4 DNA ligase, Roche) into the pT1NX plasmid at the BamH1/Spe1 site. Recombinant plasmids were electroporated into competent L. lactis strain MG1363, which was further plated on erythromycin-containing M17 plates for positive selection. Recombinant L. lactis was verified by PCR using primers Lcn2-start 5 0 GTCCTGGGCCTGGCTCTG3 0 and pT1NX-start AGTCATACTTTCTGCTGCAG (targets upstream end of Lcn2 transgene), and Lcn2-stop CTCTGGGCCTCAAGGACG and pT1NX-stop TTTCGGGCTTTGTTAGCAGC (targets downstream end of Lcn2 transgene). Plasmid was further purified from isolated clones, and transgene presence was verified by BamH1/Spe1 digestion and agarose gel electrophoresis.
Characterization of Lcn2 Expression in L. lactis
Recombinant Lcn2-expressing L. lactis (Lactis Lcn2 ) and L. lactis transformed with empty plasmid (Lactis Con ) were cultured in selective M17 media as described in the Bacteria section for 24 and 48 hours. Cultures were centrifuged at 10,000g for 5 minutes, and the cell supernatant and pellet were collected. The supernatant was treated with 100 mL of 100% trichloroacetic acid and incubated for 10 minutes on ice to precipitate proteins. The supernatant protein precipitate and cell pellet were resuspended in radioimmunoprecipitation assay (RIPA) buffer (Cell Signaling) containing protease inhibitor cocktail (Roche). Western blotting was performed by standard methods using 4% to 20% gel (Bio-Rad, Hercules, CA) and murine Lcn2 polyclonal antibody. The concentration of secreted Lcn2 was quantitated using Lcn2 Duoset ELISA kit according to the manufacturer's protocol. Cell lysates and culture supernatant of L. lactis transformed with empty plasmid (referred as Lactis Con ) were used as controls.
Sample Preparation, Labeling, and Twodimensional Gel Electrophoresis Protein lysates were obtained from Lactis Lcn2 and Lactis Con . Briefly, Lactis Lcn2 and Lactis Con were pelleted and proteins were extracted by sonication in a lysis buffer (0.5 mM EDTA, 50 mM Tris-HCl, 50 mM NaCl, 1 mM dithiothreitol (DTT), 5% glycerol). Protein samples were prepared using 2D-clean-up for subsequent 2D analysis. For 2D-cleanup, 100 mg of proteins was precipitated, purified, and cleaned by a 2D-clean-up kit (GE Healthcare, Piscataway, NJ) according to the manufacturer's protocol. Pellets of precipitated proteins were resuspended in 60 mL of rehydration buffer (7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 25 mM Tris-HCl pH 8.8). Twenty-five micrograms of Lactis Lcn2 or Lactis Con samples was labeled with 200 pmol N-hydroxy-succinimidyl ester of cyanine dye Cy3 and with 200 pmol N-hydroxy-succinimidyl ester of cyanine dye Cy5, respectively (GE Healthcare Life Sciences, Piscataway, NJ). After quenching with 10 mM lysine, the labeled proteins were mixed. Sample buffer (7 M urea, 4 M thiourea, 4% CHAPS, 2% DTT, 2% immobilized pH gradient (IPG) buffer, pH 4-11 NL [GE Healthcare Life Sciences]) and rehydration solution (7 M urea, 4 M thiourea, 4% CHAPS, 1% DTT, 1% IPG) were added to a final volume of 350 mL for each gel. First-dimension isoelectric focusing was performed using 24-cm IPG strips (pH 4-7, GE Healthcare Life Sciences) in Ettan IPGphor (GE Healthcare Life Sciences). After isoelectric focusing, the strips were equilibrated, reduced, alkylated, and stained by sequential incubation in 1.5% DTT equilibration buffer (50 mM Tris-HCl, pH 8.8) (6 M urea, 30% glycerol, and 2% sodium dodecyl sulfate) and 4.5% iodoacetamide equilibration buffer slightly colored with bromophenol blue for 20 minutes each. The second-dimension sodium dodecyl sulfate polyacrylamide gel electrophoresis was conducted on a 10% polyacrylamide gel in the Ettan DALT II system separation unit (GE Healthcare Life Sciences) until the tracking dye reached the bottom of the gel. After completion of two-dimensional electrophoresis, gel images were acquired on a Typhoon Trio (GE Healthcare Life Sciences) at appropriate wavelengths for Cy3 and Cy5 dyes and analyzed using DeCyder image analysis software (v. 7.0; GE Healthcare Life Sciences).
Quantification of Bacterial Growth
Overnight-grown recombinant Lactis Lcn2 and Lactis Con (1 · 10 6 CFU) were placed into selective M17 media prepared at different pH (4.0-8.0) or in the presence of primary bile salts (taurocholate or glycocholate; 0-100 mM) or secondary bile salts (lithocholate and deoxycholate; 0-0.1 mM) and then incubated under anaerobic conditions at 308C for 5 hours. Optical density was measured every hour to assess bacterial growth at 600 nm.
Measurement of Bacterial Viability in the Presence of Hydrogen Peroxide
Overnight-grown recombinant Lactis Lcn2 and Lactis Con (1.0 · 10 6 CFU) were incubated with H 2 O 2 (0-10 mM) for 5 hours in selective M17 media under aerobic or anaerobic conditions at 308C. Viable cells were determined by comparing optical density at 600 nm of H 2 O 2 treated and nontreated in each 1 hour time point.
In vitro MPO-mediated Bacterial Killing Assay
The MPO-mediated bacterial killing assay was performed as described by Atosuo and Lilius. 24 Briefly, the reaction mixture was prepared by first adding MPO (5.0 mg/mL) in sterile phosphate-buffered saline. H 2 O 2 (30 mM) was next added and incubated at room temperature for 5 minutes. Finally, overnightgrown recombinant Lactis Lcn2 or Lactis Con (1.0 · 10 6 CFU) was added to the reaction mixture. After 5 hours of incubation at 308C, the reaction mixture was serially diluted and plated on selective M17 agar plates in triplicates. Plates were incubated overnight at 308C, and the bacterial CFUs were quantified.
Determination of Bacterial Iron Content
The cellular iron content was measured in bacterial lysates from overnight-grown Lactis Lcn2 and Lactis Con cultures. 25 Briefly, an equal amount of protein lysates (Lactis Lcn2 or Lactis Con ) was mixed with an equivalent volume of solution containing hydrochloric acid (0.1 mg/mL), trichloroacetic acid (1.0 mol/L), and thioglycolic acid (30 mL/L) to precipitate proteins and released protein-bound iron. After centrifugation at room temperature (6200g for 15 minutes), the supernatants were collected and mixed with an equal volume of chromogen solution containing 1.5 M ferrozine and 1.5 M sodium acetate. The optical density of the chromogen was measured at 562 nm. Total iron levels were estimated using a standard curve generated with the iron atomic absorption standard (0-5 mg/mL).
MPO Inhibition Assay
Bacterial cell lysates (Lactis Lcn2 and Lactis Con , 5.0 mg of protein) and Ent (10 mM) were preincubated with MPO (100 mU, final concentration) for 5 minutes. The MPO reaction was initiated by adding final concentrations of 100 mM guaiacol and 6.7 · 10 23 % H 2 O 2 . The change in absorbance at 470 nm was measured over a period of 10 minutes at 1-minute intervals. MPO activity determined using the guaiacol method was calculated as previously described. 26 E. coli K12 Growth Inhibition Assay E. coli K12 strain MG1655 (1 · 10 6 CFU) was grown in the presence or absence of bacterial lysates (Lactis Lcn2 or Lactis Con , 5.0 mg of protein) for 5 hours in LB media at 378C. Bacterial growth was determined by measuring optical density at 600 nm every hour.
Chrome Azurol S Assay
Chrome azurol S (CAS) agar plates were prepared according to the protocol as described previously. 27 Overnight bacterial cultures grown in LB media were placed on CAS agar plates at indicated concentrations in the absence or presence of Lactis Lcn2 or Lactis Con , incubated overnight at 378C and monitored for orange-colored halo formation. CAS gives a unique blue color when in complex with iron but turns orange when bacterial siderophores (e.g., Ent) chelate with the iron from CAS. The intensity of orange halo formation is directly proportional to the concentration of siderophores secreted by the live bacteria.
DSS-induced Colitis Model
Female WT mice (6-8 weeks old, n ¼ 6) were administered 1.5% DSS in drinking water to induce acute colitis as described previously. 28 Briefly, mice were treated with 1 cycle of 1.5% DSS (MP Biological) in drinking water for 7 days followed by regular water for 4 days. Induction of colonic inflammation was confirmed through fecal occult blood, diarrhea, and loss in body weight. For the therapeutic study, mice were administered with Lactis Lcn2 or Lactis Con (1.0 · 10 8 CFU/mouse) through oral gavage once on the following days on withdrawal of DSS treatment. After 4 days of bacteria administration, mice were euthanized and severity of colitis was analyzed.
Euthanasia and Blood Collection
At the termination of the experiment, mice were euthanized using CO 2 asphyxiation and analyzed for standard colitis parameters as described previously. 29 Blood was collected at the time of euthanasia in BD Microtainer (Becton, Dickinson, Franklin Lakes, NJ), via retro-orbital plexus. Hemolysis-free sera were obtained after centrifugation and stored at 2808C until further used.
Bacterial Quantification in Fecal Samples, Cecal Content, and Colonic Mucosa
Fecal samples from Lactis Lcn2 -or Lactis Con -treated colitic mice were collected at 48, 72, and 96 hours postinoculation. Cecal content and colonic tissue were collected on the day of euthanasia and homogenized in sterile phosphate-buffered saline (100 mg/mL). The fecal, cecal, and colon homogenates were centrifuged at 200 rpm for 1 minute and plated (100 mL) on selective M17 agar plates. Plates were incubated overnight at 308C, and bacterial CFUs were quantified.
Colonic MPO Assay
MPO assay was performed according to the previously described method. 26 Briefly, frozen or fresh colon tissue (50 mg) was homogenized in 1 mL of 50 mM potassium phosphate buffer (pH 6.0) containing 0.5% hexadecyl trimethyl ammonium bromide, freeze-thawed 3·, sonicated, centrifuged (10,000g, 48C), and the clear supernatants were collected. The reaction was initiated by adding final concentrations of 50 mM guaiacol and 0.002% H 2 O 2 to the clear supernatant prepared in a 96-well plate (Corning, Corning, NY). The change in absorbance at 470 nm was measured over a period of 10 minutes at 1-minute intervals. One unit of MPO activity is defined as the amount that increases absorbance at 470 nm by optical density of 1.0 per minute at 258C, calculated from the initial rate of reaction.
Enzyme-linked Immunosorbent Assay
Serum KC and SAA were measured by ELISA kits according to the manufacturer's protocols. Frozen or freshly collected feces were reconstituted (100 mg/mL) in phosphatebuffered saline containing 0.1% Tween 20, vortexed (30 minutes, room temperature), and centrifuged (10,000g, 48C) to collect clear supernatants for fecal Lcn2 quantification as described previously. 3 Quantitative Reverse-Transcriptase Polymerase Chain Reaction
Mouse distal colons were collected in RNAlater. Total colonic RNA was extracted using TRI Reagent as per the manufacturer's protocol. Purified RNA was used to synthesize cDNA for quantitative reverse-transcriptase polymerase chain reaction using SYBR Green mix according to the manufacturer's protocol. Quantitative reverse-transcriptase polymerase chain reaction was performed in StepOnePlus real-time PCR instrument (Life Technologies, Grand Island, NY). Sequences of primers used for quantitative reverse-transcriptase polymerase chain reaction were (sense and antisense, respectively): KC 5 0 -TTGTGCGAAAAGAAGTGCAG-3 0 , and reverse, 5 0 -TACAAA-CACAGCCTCCCACA-3 0 ; tumor necrosis factor alpha 5 0 -ACTCCAGGCGGTGCCTATGT-3 0 and 5 0 -AGTGTGAGG-GTCTGGGCCAT-3 0 ; iNOS 5 0 -TTTGCTTCCATGCTAATGC-GAAAG-3 0 , and 5 0 -GCTCTGTTGAGGTCTAAAGGCTCCG-3 0 ; 36B4 5 0 -TCCAGGCTTTGGGCATCA and 5 0 -CTTTATTCA-GCTGCACATCACTCAGA-3 0 . Thermal profile for the reaction was initial denaturation at 958C for 3 minutes and 40 cycles of denaturation (958C for 15 seconds) and annealing and extension (608C for 1 minute). Relative fold difference between groups was calculated using the comparative Ct (2 2DDCt ) method. Results obtained were normalized with the housekeeping 36B4 gene.
Histology
Swiss rolls of colons were fixed in 10% buffered formalin (Fisher Scientific, Bellefonte, PA) overnight and then stored in 70% ethanol. Paraffin-embedding tissue sections (5 mm) were stained with hematoxylin and eosin using standard protocols at the Animal Diagnostics Laboratories, Pennsylvania State University. To detect the presence of acidic mucin in the goblet cells, alcian blue staining (pH 2.5) was performed in 5 mm section of a Swiss roll made from the colon using Alcian Blue (pH 2.5) Stain Kit from Vector Laboratories (Burlingame, CA). Histological scoring for colonic inflammation was graded as described previously 30,31 based on intestinal lesions, inflammation, mucosa, and percentage of affected area.
Statistical Analysis
All experimental results were reproduced in at least 3 independent experiments performed in triplicate. All values in the results are expressed as mean 6 SEM. Statistical significance between 2 groups was analyzed using unpaired, 2-tailed t test. Data from more than 2 groups were compared using a 1-way analysis of variance followed by Dunnett's post hoc test (when to compare the mean of each column with the mean control column) or Tukey's multiple comparison tests (when to compare the mean of each column with the mean of every other column). P , 0.05 was considered as statistically significant. All statistical analyses were performed with the GraphPad Prism 7.0 program (GraphPad, Inc., La Jolla, CA).
RESULTS
Generation L. lactis Producing Lcn2
Overexpression of Lcn2 has been demonstrated to enhance cellular resistance to oxidative stress and apoptosis in various mammalian cell lines. [32] [33] [34] [35] [36] To investigate whether Lcn2 could be exploited to augment the stability of probiotic bacteria, we have engineered recombinant L. lactis strain expressing either the murine Lcn2 (Lactis Lcn2 ) or the empty plasmid as control (Lactis Con ). The pT1NX plasmid used herein is a well-characterized secretion vector for L. lactis. Accordingly, we inserted the Lcn2 gene into the pT1NX plasmid at the BamH1/Spe1 site downstream of the P1 promoter and USP45 signal sequence (Fig.  1A) . Construction of Lcn2 under the P1 promoter allows for constitutive expression, whereas USP45 encodes for the sequence signal to drive the secretion of Lcn2 from L. lactis. In addition, the pT1NX plasmid contains the erythromycin resistance gene, which allowed positive selection for Lactis Lcn2 and Lactis Con .
We verified that the growth curves of Lactis Lcn2 and Lactis Con were comparable, which indicate that the expression of Lcn2 did not impede the growth of L. lactis (Fig. 1B) . Immunoblot of Lactis Lcn2 cell lysates confirmed the expression of Lcn2 as ;25 and 50 kDa bands (Fig. 1C) which corresponded to the monomeric and dimeric forms of Lcn2, 37, 38 respectively. Although the levels of intracellular Lcn2 in Lactis Lcn2 remained unchanged from 24 to 48 hours of culture (Fig. 1D ), they were higher in the culture supernatant at 48 hours than at 24 hours (Fig.  1E) , suggesting that Lcn2 accumulated extracellularly over time on secretion or released from lysed bacteria. The appearance of the Lcn2 band from Lactis Lcn2 with molecular weight lesser than 25 kDa could be due to the lack of posttranslational modification, such as glycosylation, in bacteria. The analysis of Lactis Lcn2 and Lactis Con cell lysates, respectively, labeled with Cy5 and Cy3 by 2D differential gel electrophoresis demonstrated that the ectopic expression of Lcn2 did not alter the overall proteome expression in Lactis Lcn2 (Fig. 1F) . The loss of the 50 kDa band in the 2D gel could be due to the use of DTT and iodoacetamide, which are strong reducing and alkylating agents, respectively, that reduce and prevent the formation of disulfide bonds in the sample preparation. In comparison, the 50 kDa band observed in the immunoblot could be potentially explained by the use of b-mercaptoethanol, which is relatively less efficient in ensuring complete removal of protein dimers.
Recombinant Lcn2 Expressed by L. lactis Is Bioactive
Among its well-characterized functions, Lcn2 is known to sequester Ent from E. coli, thus preventing their acquisition of iron and inhibiting their growth. Hence, we first investigated the bioactivity of Lactis Lcn2 -derived Lcn2 by assessing its antimicrobial and Ent-sequestering properties. Indeed, the cell lysates from Lactis Lcn2 , but not Lactis Con , significantly inhibited the growth of E. coli K12 (MG1655; Lcn2-sensitive strain, Fig.  2A ). We next assessed the ability of Ent to inhibit neutrophil MPO in the presence of Lactis Lcn2 cell lysates. Previously, we have shown that Ent can inhibit the MPO activity by interfering the peroxidase-catalyzed reaction; Ent interferes with compound I [oxoiron, Fe(IV)O] and reverts the enzyme back to its native ferric [Fe(III)] state. 26 Consistent with our previous report, 26 10 mM of Ent inhibited MPO activity by approximately 60% (Fig. 2B) . However, the addition of cell lysates from Lactis Lcn2 , but not Lactis Con , rescued the MPO activity from Ent-mediated inhibition (;10% inhibition; Fig. 2B ), thus implicating that Lactis Lcn2 -derived Lcn2 is bioactive in sequestering Ent and neutralizes its bioactivity.
To verify these findings, we cocultured the recombinant L. lactis with Ent-overproducing E. coli (DfepA mutant; K12) on CAS media that detects siderophore production. The formation of orange halo due to iron-chelating Ent from DfepA E. coli was not affected when cocultured with the control Lactis Con . However, the presence of Lactis Lcn2 dose dependently inhibited the size of the halo formed by DfepA E. coli, which further confirms the bioactivity of Lactis Lcn2 -derived Lcn2 (Fig. 2C) .
Intriguingly, we observed that Lactis Lcn2 on CAS media could also form a halo, indicative of iron-binding property, although L. lactis is not known to produce any siderophore 39, 40 ( Fig. 2C) . This observation correlates with the approximately 100-fold increase in intracellular iron levels in Lactis Lcn2 compared with Lactis Con (Fig. 2D) . Because Lactis Lcn2 lacks the mechanism to uptake the secreted Lcn2, it is unlikely that Lcn2 could facilitate iron intake. Instead, we envisioned that the cytosolic Lcn2 might have trapped the iron in the cell, thus resulting in the accumulation of cellular iron. The ability of Lactis Lcn2 to sequester and possibly deplete iron bioavailability may further explain their capability to inhibit the growth of E. coli in vitro.
Lcn2-expressing L. lactis Displays Enhanced Tolerance to Environmental Stressors
The efficacy of probiotic bacteria can be significantly mitigated by deficiencies to withstand the harsh environmental stressors in the gut, especially the inflammatory environment encountered during IBD. Several studies have reported that Lcn2 overexpression in various mammalian cell lines could enhance their cellular resistance to oxidative stress. 34, 35 Hence, we sought to investigate whether the expression of Lcn2 would confer any advantage to Lactis Lcn2 against adverse conditions. Alteration in extracellular pH, for instance, could induce cellular stress and impede bacterial growth. 41 Although we observed Lactis Con to be sensitive to pH changes, we noted that Lactis Lcn2 could grow more robustly over a range of physiological pH levels (pH 5-8; Fig. 3A ) in vitro. The growth advantage of Lactis Lcn2 over Lactis Con at adverse pH could be possibly due to reduced pH-mediated stress in the presence of Lcn2. FIGURE 2. Lcn2 produced by Lactis Lcn2 is bioactive: (A) line graph represents the growth curve for E. coli cultured in the presence of cell lysates (5 mg of protein) from Lactis Lcn2 , Lactis Con , or vehicle control. MPO (100 mU) was preincubated with Ent (10 mM) and cell lysates (5 mg of protein) from Lactis Lcn2 or Lactis Con for 5 minutes before the assay was initiated. B, Bar graph represents % MPO activity. C, Orange halo formation indicates siderophore production by DfepA E. coli mutant on CAS plate (cultured overnight, 378C) in the presence of Lactis Lcn2 , Lactis Con , or vehicle control at the indicated CFU concentration/ratio. D, The cellular iron levels were measured in the cell lysates from Lactis Lcn2 and Lactis Con . All experiments were performed in triplicates and are representative of 3 independent experiments. Results are expressed as mean 6 SEM. *P , 0.05.
Aside from pH changes, bacteria traversing the gastrointestinal tract could be exposed to primary bile salts (i.e., taurocholate and glycocholate) that are toxic to most bacteria. 42 Indeed, 0.001 mM of taurocholate and glycocholate was sufficient to significantly inhibit the growth of Lactis Con in vitro (Fig. 3B,  C) . In comparison, Lactis Lcn2 could better tolerate high concentrations of taurocholate and glycocholate up to 10 mM and only displayed reduced growth in the presence of 100 mM of taurocholate and glycocholate in vitro (Fig. 3B, C) . Although most of the primary bile acids are reabsorbed by the small intestine, a fraction of these bile acids are metabolized by intestinal bacteria into secondary bile acids, such as deoxycholate and lithocholate 43 which could inhibit bacterial growth. Interestingly, we observed that Lactis Lcn2 could also better withstand the presence of lithocholate and deoxycholate at concentrations ranging from 0.001 to 0.1 mM in vitro, when compared with Lactis Con (Fig. 3D, E) .
In the context of experimental colitis, many probiotics and gut bacteria would be exposed to reactive oxygen species generated by immune and nonimmune cells in the inflamed gut. To assess whether Lcn2 expression in L. lactis exerts antioxidative effects, we next challenged Lactis Lcn2 and Lactis Con with a range of oxidizing conditions. The viability of both Lactis Lcn2 and Lactis Con decreased dose dependently with increasing H 2 O 2 concentrations, yet Lactis Lcn2 consistently survived better than FIGURE 3. Lcn2-expressing L. lactis (Lactis Lcn2 ) exhibits augmented resistance to various stressors: Equal amount of Lactis Lcn2 or Lactis Con (1 · 10 6 CFU) was cultured at the indicated (A) pH or in the presence of (B) taurocholate, (C) glycocholate, (D) lithocholic acid, and (E) deoxycholic acid at the indicated concentration. Lactis Lcn2 or Lactis Con was subjected to the indicated concentration of (F) H 2 O 2 , (G) H 2 O 2 with aeration, and (H) MPOmediated bacterial killing. All experiments were performed in triplicates and are representative of 3 independent experiments. Results are expressed as mean 6 SEM. *P , 0.05.
Lactis Con (Fig. 3F) . When the assay was performed with 1.25 mM H 2 O 2 under aerobic conditions (Fig. 3G) , we observed that the viability of Lactis Con decreased from 40% (without aeration) to 20% (with aeration). This outcome is expected because the presence of O 2 in the aerated culture generates reactive oxygen species, such as H 2 O 2 , OH, and O 2 , which are unfavorable for L. lactis. However, 1.25 mM H 2 O 2 -treated Lactis Lcn2 was able to better withstand aeration with a slight decrease in viability from 65% to 55% (Fig. 3G) . When the H 2 O 2 concentration was increased to 2.5 mM with aeration, the viability of Lactis Lcn2 decreased to 30%, whereas Lactis Con displayed only 10% viability (Fig. 3G ). Next, we tested the extent to which Lactis Lcn2 and Lactis Con can survive bacterial killing by neutrophil MPO, an oxidative enzyme which uses H 2 O 2 and halide ions to generate hypochlorous acid. 44 As anticipated, Lactis Lcn2 displayed a higher capacity to remain viable (80%) than Lactis Con (40%), even when exposed to MPO-H 2 O 2 -mediated antimicrobial activity (Fig. 3H ).
Lcn2 Expression Allows L. lactis to Colonize and Survive Better in the Inflamed Gut
To assess the survivability of Lactis Lcn2 in the inflamed gut, we first induced colitis in 8-week-old female WT mice (n ¼ 6) through administration of low dose of DSS (1.5%) in drinking water for 7 days. The induction of acute colitis was confirmed by the presence of occult blood and body weight loss. DSS treatment was withdrawn on day 7, and mice were maintained on regular drinking water. On the next day, the mice were orally administered with Lactis Lcn2 or Lactis Con (1.0 · 10 8 CFU/mouse), and fecal shedding of these bacteria was monitored. Interestingly, the fecal shedding of Lactis Lcn2 was more robust and persisted up to 96 hours postinoculation when compared with Lactis Con (Fig. 4A) . To verify the colonization capacity of Lactis Lcn2 and Lactis Con in the inflamed gut, we next measured their bacterial load in the cecal content and colonic tissue. Our results showed that Lactis Lcn2 can colonize in the colonic mucosa, in a more efficient manner than Lactis Con (Fig. 4B) . Lactis Lcn2 also colonized more robustly than Lactis Con in the ceca (Fig. 4C) . We next recovered the Lactis Lcn2 from colitic mice and confirmed that it retained its Lcn2 expression (Fig. 4D) . We next evaluated their tolerance to H 2 O 2 exposure to assess whether Lactis Lcn2 recovered from colitic mice retained their oxidant-resistant phenotype. Consistent with our previous findings, the recovered Lactis Lcn2 exhibited greater resistance to H 2 O 2 in vitro than the recovered Lactis Con (Fig. 4E ).
Lcn2-expressing L. lactis Accelerates Mice Recovery from DSS-induced Acute Colitis
Having established that Lactis Lcn2 can survive and colonize the inflamed gut, we next investigated the therapeutic potential of Lactis Lcn2 in attenuating intestinal inflammation in comparison with Lactis Con . First, we verified that the sole inoculation of Lactis Lcn2 and Lactis Con into healthy mice did not result in diarrhea, colomegaly, or splenomegaly (data not shown). Next, we performed DSS-induced colitis with 8-week-old female WT mice (n ¼ 6), as described in the Material and Methods DSS-induced Colitis Model section. After confirming the onset of colitis on day 7, DSS was withdrawn, and mice were orally administered with Lactis Lcn2 or Lactis Con (1.0 · 10 8 CFU/mouse) therapeutically. Mice were monitored for body weight for another 4 days and then euthanized. We did not observe any significant difference in body weight gain/loss in Lactis Lcn2 -or Lactis Con -treated mice when compared with DSS-alone given mice (Fig. 5A) . However, the treatment with Lactis Lcn2 , but not Lactis Con , successfully mitigated the splenomegaly, colon shortening, and colonic MPO activity that are associated with DSS-induced acute colitis (Fig.  5B-F) . Given that Lactis Lcn2 was administered after DSS-induced colon shortening had already occurred, it is thus possible that Lactis Lcn2 treatment may either prevent further shortening of the colon or promote the recovery, including restoration of colon length. In comparison with Lactis Lcn2 -treated mice, the mice receiving Lactis Con displayed only modest amelioration of colitis in all parameters analyzed. Histological (hematoxylin and eosin) analysis indicated that the colitis in DSS+Lactis Lcn2 -treated mice was less severe, when compared with DSS-alone and DSS+Lactis Con -treated mice (Fig. 5G, I ). Similarly, the number of mature goblet cells containing large mucosal granules, as evident with Alcian blue staining, was markedly increased in DSS+Lactis Lcn2 -treated mice compared with the DSS-alone and DSS+Lactis Con -treated mice (Fig. 5H) .
To further assess the effect of Lactis Lcn2 on colitis, we evaluated a panel of systemic and colonic markers that correlate with the severity of inflammation. Colitic mice therapeutically treated with either Lactis Lcn2 or Lactis Con displayed a significant decrease in levels of serum KC (Fig. 5J) . The levels of SAA were also substantially reduced in Lactis Lcn2 -treated mice compared with those in Lactis Con -treated mice (Fig. 5K) . Furthermore, the colonic expression of inflammatory genes such as KC, tumor necrosis factor alpha, and inducible nitric oxide synthase (iNOS) was reduced in both Lactis Lcn2 -and Lactis Con -treated mice, although their downregulation was slightly more pronounced in the Lactis Lcn2 -given mice (Fig. 5L-N) .
DISCUSSION
Intestinal inflammation is accompanied with systemic hypoferremia as an acute-phase response to deplete circulating iron and prevent iron-induced oxidative stress. Such state of iron deficiency substantially affects the composition of gut bacteria because iron is an essential micronutrient for almost all microorganisms, except Borrelia species and most lactic acid bacteria. 45, 46 During this iron-deprived state, the opportunistic pathogen E. coli produces Ent, a siderophore, to acquire the iron from the host and thereby possess survival advantage in the inflamed gut. On the flip side, the host relies on the innate immune protein Lcn2 to sequester Ent and curtail the overgrowth of E. coli. In comparison, L. lactis is largely unaffected by the antimicrobial activity of Lcn2 because L. lactis neither requires iron nor expresses any siderophore. 39, 40 However, the inability of L. lactis to respond to iron status in the gut microenvironment would allow it to be rapidly outcompeted by E. coli and other iron-responsive bacteria in the inflamed gut. 47 In this study, we have engineered L. lactis to express Lcn2 (Lactis Lcn2 ) as an innovative strategy to augment the fitness and efficacy of L. lactis in mitigating gut inflammation.
Given its small size (25 kDa) and the lack of posttranslational modification requirement, Lcn2 presents a feasible candidate to be expressed in bacteria. We considered the foodgrade L. lactis as the ideal vector strain because it is Gram positive (endotoxin free), nonpathogenic, noninvasive and is a transient colonizer having probiotic properties. Most importantly, the lack of iron requirement and siderophore expression in L. lactis 39, 40 ensures that recombinant Lcn2 would be secreted in its active form that is free from iron and siderophore. We noted that Lactis Lcn2 is capable of producing both the monomeric and dimeric forms of Lcn2, albeit the dimeric form was noticeably more abundant within the cell lysates. 5. Lcn2-expressing L. lactis protects against DSS-induced mucosal injury: 8-week-old female BL6 WT mice (n ¼ 6) were given 1.5% DSS in drinking water for 7 days. After cessation of DSS on day 7, mice were maintained on regular water. On day 8 onward, mice were orally administered with Lactis Lcn2 or Lactis Con (1 · 10 8 CFU/mouse) once daily. The following parameters were analyzed: (A) body weight, (B) gross colon, (C) spleen weight, (D) colon length, (E) colonic MPO activity, and (F) colonic MPO protein level. Histology images of (G) hematoxylin and eosin (H&E)-stained and (H) Alcian blue-stained colons. I, Histological scores of H&E-stained colons. In vitro assays were performed in triplicates and are representative of 2 independent mouse experiments. The perceptive markers of intestinal inflammation: (J) serum KC and (K) SAA were measured by ELISA. The quantitative reversetranscriptase polymerase chain reaction analysis was used to measure the mRNA expression of colonic (L) KC, (M) tumor necrosis factor alpha (TNF-a), and (N) iNOS. Values are represented as fold change normalized to 36B4 housekeeping gene and compared with the control group. In vitro assays were performed in triplicates and are representative of 2 independent mouse experiments. Results are expressed as mean 6 SEM. *P , 0.05.
Although the functional differences between monomeric and dimeric forms of Lcn2 are yet to be clarified, 37, 38 our in vitro assays nonetheless confirmed that Lactis Lcn2 -derived Lcn2 is indeed bioactive in inhibiting the growth of E. coli and mitigating Ent bioactivity. Rather intriguingly, the expression of Lcn2 seemed to confer L. lactis with the ability to sequester iron from its microenvironment. Lcn2 alone, however, does not bind iron directly but requires siderophores as cofactors to form an "Lcn2-siderophore-iron" ternary complex. The accumulation of iron in L. lactis hence implies the involvement of an unknown siderophore, either generated by the bacterium or acquired from the media, which needs to be further investigated for its role in facilitating iron chelation by Lcn2 in Lactis Lcn2 . Nevertheless, the ability of Lcn2 to augment iron responses of L. lactis may be beneficial in allowing it to compete better with other iron-dependent bacteria in the gut. 47 Aside from its antimicrobial functions, Lcn2 overexpression has been demonstrated to enhance cellular resistance to oxidative stress and iron-induced toxicity in various mammalian cell lines. [32] [33] [34] [35] [36] 48, 49 As anticipated, the expression of Lcn2 substantially increased the capacity of Lactis Lcn2 to tolerate adverse conditions, including extreme pH, exposure to high concentrations of bile acids, oxidizing environments, and MPO-mediated bacterial killing in vitro. The cytoprotective properties of Lcn2 are not well understood, although several studies had associated its beneficial effects to its ability to modulate the labile iron pool and to exert antioxidative properties. [32] [33] [34] [35] [36] 48, 49 The changes in extracellular pH, for instance, could cause a fraction of lactic acid to become protonated, which enters and accumulates in the bacteria, thus triggering stress. 41 In this regard, we surmise that the growth advantage of Lactis Lcn2 over Lactis Con at adverse pH could be possibly due to the mitigation of pH-mediated stress in the presence of Lcn2 acting as an antioxidant. We also presumed that similar antioxidant properties of Lcn2 may also increase the capacity of Lactis Lcn2 to tolerate the adverse oxidizing conditions tested in this study. In addition, the survival of Lactis Lcn2 , in the large intestine, was more in the DSS-given mice than Lactis Con . More importantly, Lactis Lcn2 administration substantially reduced the severity of DSS-induced colitis in mice when compared with Lactis Con , suggesting that the increased fitness of Lactis Lcn2 in colonizing the inflamed gut with a higher retention rate could, in part, contribute to the better amelioration of colitis. These findings provide evidence that successful colonization and fitness of recombinant probiotic bacteria in the inflamed gut is an important consideration when optimizing probiotic regimens.
Lcn2 primarily controls the gut bacterial overgrowth by limiting its iron uptake and also mediates facilitation of the hypoferremia during inflammation. 12 In addition, Lcn2 serves as an indispensable factor for proper neutrophil migration, adhesion, and function. 50 In our recent study 16, 38 as well as others, 17, 51 Lcn2 has been demonstrated to mediate an essential role in maintaining gut homeostasis, whereas its deficiency increases their susceptibility to colitis in mice. Considering that endogenous Lcn2 is significantly upregulated during IBD, 2, 3 it is, therefore, unlikely that the delivery of additional Lcn2 through L. lactis per se could adequately account for the therapeutic properties of Lactis Lcn2 . Our findings suggested that the beneficial effects of Lactis Lcn2 could be potentially explained, at least in part, by the augmented survival or colonization ability of the probiotic L. lactis that expresses Lcn2. Nevertheless, we could not rule out the possibility that exogenous Lcn2 may also provide mucoprotective effects to the host through (1) mitigating gut dysbiosis such as preventing the bloom of Enterobacteriaceae (e.g., E. coli), 4, 10 (2) restricting luminal iron and the labile iron pool, 12 thus attenuating iron-induced oxidative stress, (3) serving as an epithelial survival factor 52 and promoting wound healing. 53, 54 Further prolonged survival may also enhance the generation of L. lactis-derived soluble, effector molecules, which can diminish gut inflammation.
Most probiotics tested in clinical trials failed to improve human IBD, 55 despite their efficacy in mitigating the gut inflammation in experimental animal models. The lack of success in the clinical setting may be explained by the inherent deficiency of these probiotics to survive against the host inflammatory responses. Such notion coincides with the consideration that many candidate probiotics are selected from bacteria that transiently colonize the gut, and thus may be rapidly depleted in the inflamed gut. In this study, we demonstrated that Lcn2 expression could be engineered into L. lactis to enhance its survivability, colonization, and capacity to tolerate the harsh environments in the inflamed gut. Overall, our findings highlight the potential for Lcn2 expression or coexpression alongside other therapeutic molecules as an innovative strategy to further stabilize probiotic bacteria that are currently studied to mitigate intestinal inflammation and allow for better management of experimental colitis.
